Liquid  ||| S:0 E:7 ||| JJ
chromatography-fluorescence  ||| S:7 E:35 ||| JJ
and  ||| S:35 E:39 ||| CC
liquid  ||| S:39 E:46 ||| JJ
chromatography-mass  ||| S:46 E:66 ||| JJ
spectrometry  ||| S:66 E:79 ||| JJ
detection  ||| S:79 E:89 ||| NN
of  ||| S:89 E:92 ||| IN
tryptophan  ||| S:92 E:103 ||| JJ
degradation  ||| S:103 E:115 ||| NN
products  ||| S:115 E:124 ||| NNS
of  ||| S:124 E:127 ||| IN
a  ||| S:127 E:129 ||| DT
recombinant  ||| S:129 E:141 ||| JJ
monoclonal  ||| S:141 E:152 ||| JJ
antibody  ||| S:152 E:161 ||| NN
Light  ||| S:161 E:167 ||| NN
exposure  ||| S:167 E:176 ||| NN
is  ||| S:176 E:179 ||| VBZ
one  ||| S:179 E:183 ||| CD
of  ||| S:183 E:186 ||| IN
several  ||| S:186 E:194 ||| JJ
conditions  ||| S:194 E:205 ||| NNS
used  ||| S:205 E:210 ||| VBN
to  ||| S:210 E:213 ||| TO
study  ||| S:213 E:219 ||| VB
the  ||| S:219 E:223 ||| DT
degradation  ||| S:223 E:235 ||| JJ
pathways  ||| S:235 E:244 ||| NN
of  ||| S:244 E:247 ||| IN
recombinant  ||| S:247 E:259 ||| JJ
monoclonal  ||| S:259 E:270 ||| JJ
antibodies ||| S:270 E:280 ||| NNS
.  ||| S:280 E:282 ||| .
Tryptophan  ||| S:282 E:293 ||| NNP
is  ||| S:293 E:296 ||| VBZ
of  ||| S:296 E:299 ||| IN
particular  ||| S:299 E:310 ||| JJ
interest  ||| S:310 E:319 ||| NN
among  ||| S:319 E:325 ||| IN
the  ||| S:325 E:329 ||| DT
20  ||| S:329 E:332 ||| CD
amino  ||| S:332 E:338 ||| CD
acids  ||| S:338 E:344 ||| NNS
because  ||| S:344 E:352 ||| IN
it  ||| S:352 E:355 ||| PRP
is  ||| S:355 E:358 ||| VBZ
the  ||| S:358 E:362 ||| DT
most  ||| S:362 E:367 ||| RBS
photosensitive ||| S:367 E:381 ||| JJ
.  ||| S:381 E:383 ||| .
Tryptophan  ||| S:383 E:394 ||| JJ
degradation  ||| S:394 E:406 ||| NN
forms  ||| S:406 E:412 ||| NNS
several  ||| S:412 E:420 ||| JJ
products ||| S:420 E:428 ||| NNS
,  ||| S:428 E:430 ||| ,
including  ||| S:430 E:440 ||| VBG
an  ||| S:440 E:443 ||| DT
even  ||| S:443 E:448 ||| RB
stronger  ||| S:448 E:457 ||| JJR
photosensitizer  ||| S:457 E:473 ||| NNS
and  ||| S:473 E:477 ||| CC
several  ||| S:477 E:485 ||| JJ
reactive  ||| S:485 E:494 ||| JJ
oxygen  ||| S:494 E:501 ||| NN
species ||| S:501 E:508 ||| NNS
.  ||| S:508 E:510 ||| .
The  ||| S:510 E:514 ||| DT
current  ||| S:514 E:522 ||| JJ
study  ||| S:522 E:528 ||| NN
reports  ||| S:528 E:536 ||| VBZ
a  ||| S:536 E:538 ||| DT
specific  ||| S:538 E:547 ||| JJ
peptide  ||| S:547 E:555 ||| JJ
mapping  ||| S:555 E:563 ||| NN
procedure  ||| S:563 E:573 ||| NN
to  ||| S:573 E:576 ||| TO
monitor  ||| S:576 E:584 ||| VB
tryptophan  ||| S:584 E:595 ||| JJ
degradation ||| S:595 E:606 ||| NN
.  ||| S:606 E:608 ||| .
Instead  ||| S:608 E:616 ||| RB
of  ||| S:616 E:619 ||| IN
monitoring  ||| S:619 E:630 ||| VBG
peptides  ||| S:630 E:639 ||| NNS
using  ||| S:639 E:645 ||| VBG
UV  ||| S:645 E:648 ||| NNP
214 nm ||| S:648 E:654 ||| NNP
,  ||| S:654 E:656 ||| ,
fluorescence  ||| S:656 E:669 ||| JJ
detection  ||| S:669 E:679 ||| NN
with  ||| S:679 E:684 ||| IN
an  ||| S:684 E:687 ||| DT
excitation  ||| S:687 E:698 ||| JJ
wavelength  ||| S:698 E:709 ||| NN
of  ||| S:709 E:712 ||| IN
295 nm  ||| S:712 E:719 ||| NNP
and  ||| S:719 E:723 ||| CC
an  ||| S:723 E:726 ||| DT
emission  ||| S:726 E:735 ||| JJ
wavelength  ||| S:735 E:746 ||| NN
of  ||| S:746 E:749 ||| IN
350 nm  ||| S:749 E:756 ||| NNP
was  ||| S:756 E:760 ||| VBD
used  ||| S:760 E:765 ||| VBN
to  ||| S:765 E:768 ||| TO
enable  ||| S:768 E:775 ||| VB
specific  ||| S:775 E:784 ||| JJ
detection  ||| S:784 E:794 ||| NN
of  ||| S:794 E:797 ||| IN
tryptophan-containing  ||| S:797 E:819 ||| JJ
peptides ||| S:819 E:827 ||| NN
.  ||| S:827 E:829 ||| .
Peaks  ||| S:829 E:835 ||| NNS
that  ||| S:835 E:840 ||| WDT
decreased  ||| S:840 E:850 ||| VBD
in  ||| S:850 E:853 ||| IN
area  ||| S:853 E:858 ||| NN
over  ||| S:858 E:863 ||| IN
time  ||| S:863 E:868 ||| NN
are  ||| S:868 E:872 ||| VBP
likely  ||| S:872 E:879 ||| JJ
to  ||| S:879 E:882 ||| TO
contain  ||| S:882 E:890 ||| VB
susceptible  ||| S:890 E:902 ||| JJ
tryptophan  ||| S:902 E:913 ||| JJ
residues ||| S:913 E:921 ||| NNS
.  ||| S:921 E:923 ||| .
This  ||| S:923 E:928 ||| DT
observation  ||| S:928 E:940 ||| NN
can  ||| S:940 E:944 ||| MD
allow  ||| S:944 E:950 ||| VB
further  ||| S:950 E:958 ||| RBR
liquid  ||| S:958 E:965 ||| JJ
chromatography-mass  ||| S:965 E:985 ||| JJ
spectrometry  ||| S:985 E:998 ||| NNS
( ||| S:998 E:999 ||| -LRB-
LC-MS ||| S:999 E:1004 ||| NNP
)  ||| S:1004 E:1006 ||| -RRB-
analysis  ||| S:1006 E:1015 ||| NN
to  ||| S:1015 E:1018 ||| TO
focus  ||| S:1018 E:1024 ||| VB
only  ||| S:1024 E:1029 ||| RB
on  ||| S:1029 E:1032 ||| IN
those  ||| S:1032 E:1038 ||| DT
peaks  ||| S:1038 E:1044 ||| NNS
to  ||| S:1044 E:1047 ||| TO
confirm  ||| S:1047 E:1055 ||| VB
tryptophan  ||| S:1055 E:1066 ||| JJ
degradation  ||| S:1066 E:1078 ||| NN
products ||| S:1078 E:1086 ||| NNS
.  ||| S:1086 E:1088 ||| .
After  ||| S:1088 E:1094 ||| IN
confirmation  ||| S:1094 E:1107 ||| NN
of  ||| S:1107 E:1110 ||| IN
tryptophan  ||| S:1110 E:1121 ||| JJ
degradation ||| S:1121 E:1132 ||| NN
,  ||| S:1132 E:1134 ||| ,
susceptibility  ||| S:1134 E:1149 ||| VBG
of  ||| S:1149 E:1152 ||| IN
tryptophan  ||| S:1152 E:1163 ||| JJ
residues  ||| S:1163 E:1172 ||| NNS
can  ||| S:1172 E:1176 ||| MD
be  ||| S:1176 E:1179 ||| VB
compared  ||| S:1179 E:1188 ||| VBN
based  ||| S:1188 E:1194 ||| VBN
on  ||| S:1194 E:1197 ||| IN
the  ||| S:1197 E:1201 ||| DT
peak  ||| S:1201 E:1206 ||| NN
area  ||| S:1206 E:1211 ||| NN
decrease ||| S:1211 E:1219 ||| NN
.  ||| S:1219 E:1221 ||| .
